BAYER AG

ISIN: DE000BAY0017 WKN: BAY001 Asset Class: Stock



Company Profile

Total assets

Bayer AG engages in the business of life science fields of healthcare and nutrition. It operates through the following segments: Crop Science, Pharmaceuticals, and Consumer Health. The Crop Science segment includes developing, producing, and marketing products in seeds and plant traits, crop protection, digital solutions, and customer services to promote sustainable agriculture. The Pharmaceuticals segment is involved in prescription products especially for cardiology and womens health; specialty therapeutics in the areas of oncology, hematology, ophthalmology, and cell and gene therapy; diagnostic imaging equipment; and necessary contrast agents. The Consumer Health segment focuses on non-prescription products in the dermatology, nutritional supplements, digestive health, allergy, cough and cold, and pain and cardiovascular risk prevention categories. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.

| Financial figures, Fiscal year: from 01.01. to 31.12. | | | | | | |
|---|----------------|------------------------------|----------------|----------------------------------|----------------|----------------------------------|
| Financial figures | | 23 Liabilities and equity | 20 Assets | 22 Liabilities and equity | 20 Assets | 21 Liabilities and equity |
| Current assets | 37,090,000,000 | | 37,247,000,000 | | 31,994,000,000 | |
| Common stock capital | | 2,515,000,000 | | 2,515,000,000 | | 2,515,000,000 |
| Fixed assets | 86,254,000,000 | | 93,637,000,000 | | 94,784,000,000 | |
| Equity capital of a company | | 33,078,000,000 | | 38,926,000,000 | | 33,168,000,000 |
| Cash and cash equivalents | 5,907,000,000 | | 5,171,000,000 | | 4,564,000,000 | |
| A named Habilitian | | 44 700 000 000 | | 40.070.000.000 | | 45.054.000.000 |

| Equity capital of a company | | 33,076,000,000 | | 36,926,000,000 | | 33,166,000,000 |
|--------------------------------|---------------|----------------|---------------|----------------|---------------|----------------|
| Cash and cash equivalents | 5,907,000,000 | | 5,171,000,000 | | 4,564,000,000 | |
| Accrued liabilities | | 11,798,000,000 | | 12,979,000,000 | | 15,951,000,000 |
| Other assets | - | | - | | - | |
| Current liabilities | | 29,457,000,000 | | 35,084,000,000 | | 29,403,000,000 |
| Prepayments and accrued income | - | | - | | - | |
| Non-current liabilities | | 60,809,000,000 | | 56,874,000,000 | | 64,207,000,000 |
| Different income | | - | | - | | - |
| Other liabilities | | 2,960,000,000 | | 3,376,000,000 | | 4,307,000,000 |

Balance notes

123,344,000,000

130,884,000,000

130,884,000,000

123,344,000,000

| | 2023 | 2022 | 2021 |
|---------------------|---------|---------|---------|
| Accounting standard | IFRS | IFRS | IFRS |
| Employees | 99,723 | 101,369 | 99,637 |
| Equity ratio | 26.94% | 29.86% | 26.28% |
| Debt-equity ratio | 271.19% | 234.92% | 280.53% |

| Others | | | |
|------------------|---------|--------|--------|
| | 2023 | 2022 | 2021 |
| Tax Expense Rate | -90.54% | 10.46% | 51.28% |

126,778,000,000

126,778,000,000

BAYER AG

ISIN: DE000BAY0017 WKN: BAY001 Asset Class: Stock

| Income statement | | | |
|--|----------------|----------------|----------------|
| | 2023 | 2022 | 2021 |
| Turnover | 47,637,000,000 | 50,739,000,000 | 44,081,000,000 |
| Net income | -2,941,000,000 | 4,150,000,000 | 1,000,000,000 |
| EBIT | -100,000,000 | 6,267,000,000 | 3,119,000,000 |
| Operating income before taxes | -1,459,000,000 | 4,820,000,000 | 1,997,000,000 |
| Cash Flow | 4,062,000,000 | 6,060,000,000 | 4,026,000,000 |
| Net interest income | -1,359,000,000 | -1,447,000,000 | -1,122,000,000 |
| Research and development expenses | 5,371,000,000 | 6,572,000,000 | 5,412,000,000 |
| Income taxes | 1,321,000,000 | 504,000,000 | 1,024,000,000 |
| Result from investments in subsidaries, associates and other | -162,000,000 | -150,000,000 | 49,000,000 |
| Revenues per employee | 477,693 | 500,538 | 442,416 |

| Board of Directors | |
|------------------------------|-------------------------------|
| | |
| Norbert Winkeljohann | Chairman of Supervisory Board |
| Barbara Gansewendt | Member of Supervisory Board |
| Ertharin Cousin | Member of Supervisory Board |
| Norbert W. Bischofberger | Member of Supervisory Board |
| Otmar Wiestler | Member of Supervisory Board |
| Paul Achleitner | Member of Supervisory Board |
| Simone Bagel-Trah | Member of Supervisory Board |
| Alberto Weisser | Member of Supervisory Board |
| Andrea Sacher | Member of Supervisory Board |
| André van Broich | Member of Supervisory Board |
| Claudia Schade | Member of Supervisory Board |
| Colleen Goggins | Member of Supervisory Board |
| Francesco Grioli | Member of Supervisory Board |
| Frank Löllgen | Member of Supervisory Board |
| Heike Hausfeld | Member of Supervisory Board |
| Heinz Georg Webers | Member of Supervisory Board |
| Horst Heinz Paul Baier | Member of Supervisory Board |
| Kimberly Marie Lein-Mathisen | Member of Supervisory Board |
| Michael Westmeier | Member of Supervisory Board |
| Yasmin Fahimi | Member of Supervisory Board |

| Members of Management Board | | | |
|-----------------------------|-------------------------------|--|--|
| | | | |
| B. Chuck Anderson | Chairman of Managing Board | | |
| Heike Prinz | Member of Executive Committee | | |
| Heiko Schipper | Member of Executive Committee | | |
| Rodrigo Santos | Member of Executive Committee | | |
| Stefan Oelrich | Member of Executive Committee | | |
| Wolfgang Nickl | Member of Executive Committee | | |